1. Home
  2. ACOG vs EPIX Comparison

ACOG vs EPIX Comparison

Compare ACOG & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACOG
  • EPIX
  • Stock Information
  • Founded
  • ACOG 2000
  • EPIX 2009
  • Country
  • ACOG Canada
  • EPIX Canada
  • Employees
  • ACOG N/A
  • EPIX N/A
  • Industry
  • ACOG
  • EPIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACOG
  • EPIX Health Care
  • Exchange
  • ACOG Nasdaq
  • EPIX Nasdaq
  • Market Cap
  • ACOG 80.3M
  • EPIX 75.9M
  • IPO Year
  • ACOG N/A
  • EPIX N/A
  • Fundamental
  • Price
  • ACOG $10.80
  • EPIX $1.72
  • Analyst Decision
  • ACOG Strong Buy
  • EPIX Hold
  • Analyst Count
  • ACOG 1
  • EPIX 3
  • Target Price
  • ACOG $20.00
  • EPIX $2.00
  • AVG Volume (30 Days)
  • ACOG 67.4K
  • EPIX 55.5K
  • Earning Date
  • ACOG 08-14-2025
  • EPIX 08-04-2025
  • Dividend Yield
  • ACOG N/A
  • EPIX N/A
  • EPS Growth
  • ACOG N/A
  • EPIX N/A
  • EPS
  • ACOG N/A
  • EPIX N/A
  • Revenue
  • ACOG $2,928,654.00
  • EPIX N/A
  • Revenue This Year
  • ACOG N/A
  • EPIX N/A
  • Revenue Next Year
  • ACOG N/A
  • EPIX N/A
  • P/E Ratio
  • ACOG N/A
  • EPIX N/A
  • Revenue Growth
  • ACOG N/A
  • EPIX N/A
  • 52 Week Low
  • ACOG $3.75
  • EPIX $1.40
  • 52 Week High
  • ACOG $11.54
  • EPIX $7.88
  • Technical
  • Relative Strength Index (RSI)
  • ACOG N/A
  • EPIX 51.31
  • Support Level
  • ACOG N/A
  • EPIX $1.68
  • Resistance Level
  • ACOG N/A
  • EPIX $1.75
  • Average True Range (ATR)
  • ACOG 0.00
  • EPIX 0.04
  • MACD
  • ACOG 0.00
  • EPIX 0.00
  • Stochastic Oscillator
  • ACOG 0.00
  • EPIX 62.50

About ACOG Alpha Cognition Inc. Common Stock

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About EPIX ESSA Pharma Inc.

ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.

Share on Social Networks: